Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR19567] to Pyrin (phospho S205)
- Suitable for: WB
- Reacts with: Mouse
Product nameAnti-Pyrin (phospho S205) antibody [EPR19567]
See all Pyrin primary antibodies
DescriptionRabbit monoclonal [EPR19567] to Pyrin (phospho S205)
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse
Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) within Mouse Pyrin aa 200-300 (phospho S205). The exact sequence is proprietary.
Database link: Q9JJ26
- WB: DC2.4 whole cell lysate expressing Pyrin (MEFV).
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.2
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 0.05% BSA, 40% Glycerol (glycerin, glycerine)
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab201784 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 110 kDa (predicted molecular weight: 86 kDa).|
FunctionProbably controls the inflammatory response in myelomonocytic cells at the level of the cytoskeleton organization.
Tissue specificityExpressed in peripheral blood leukocytes, particularly in mature granulocytes and to a lesser extent in monocytes but not in lymphocytes. Detected in spleen, lung and muscle, probably as a result of leukocyte infiltration in these tissues. Not expressed in thymus, prostate, testis, ovary, small intestine, colon, heart, brain, placenta, liver, kidney, pancreas. Expression detected in several myeloid leukemic, colon cancer, and prostate cancer cell lines.
Involvement in diseaseDefects in MEFV are the cause of familial Mediterranean fever autosomal recessive (ARFMF) [MIM:249100]. ARFMF is an inherited disorder characterized by recurrent episodic fever, serosal inflammation and pain in the abdomen, chest or joints. ARFMF is frequently complicated by amyloidosis, which leads to renal failure and can be prophylactically treated with colchicine. ARFMF primarily affects ancestral ethnic groups living around the Mediterranean basin: North African Jews, Armenians, Arabs and Turks. The disease is also distributed in other populations including Greeks, Cypriots, Italians and Spanish, although at a lower prevalence.
Defects in MEFV are the cause of familial Mediterranean fever autosomal dominant (ADFMF) [MIM:134610]. ADFMF is characterized by periodic fever, serosal inflammation and pain in the abdomen, chest or joints as seen also in the autosomal recessive form of the disease. It is associated with renal amyloidosis and characterized by colchicine unresponsiveness.
Sequence similaritiesContains 1 B box-type zinc finger.
Contains 1 B30.2/SPRY domain.
Contains 1 DAPIN domain.
Developmental stageFirst detected in bone marrow promyelocytes. Expression increases throughout myelocyte differentiation and peaks in the mature myelomonocytic cells.
Cellular localizationNucleus and Cytoplasm > cytoskeleton. Associated with microtubules and with the filamentous actin of perinuclear filaments and peripheral lamellar ruffles.
- Information by UniProt
- FMF antibody
- Marenostrin antibody
- Mediterranean fever antibody
All lanes : Anti-Pyrin (phospho S205) antibody [EPR19567] (ab201784) at 1/1000 dilution
Lane 1 : Cell lysate of DC2.4 (Mouse immature dendritic cell line) expressing mPyrin (MEFV)
Lane 2 : Cell lysate of DC2.4 (Mouse immature dendritic cell line) expressing mPyrin (MEFV) and mPyrin (MEFV) is dephosphorylated by stimulation with TcdA
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 86 kDa
Observed band size: 110 kDa why is the actual band size different from the predicted?
Exposure time: 1 second
Blocking/Dilution buffer: 5% NFDM/TBST.
The lysates were kindly provided by Feng Shao, National institute of biological sciences Beijing, China.
ab201784 has been referenced in 3 publications.
- Medici NP et al. Characterization of Pyrin Dephosphorylation and Inflammasome Activation in Macrophages as Triggered by the Yersinia Effectors YopE and YopT. Infect Immun 87:N/A (2019). PubMed: 30602502
- Medici NP & Bliska JB Methods for Detection of Pyrin Inflammasome Assembly in Macrophages Infected with Yersinia spp. Methods Mol Biol 2010:241-255 (2019). PubMed: 31177443
- Gao W et al. Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation. Proc Natl Acad Sci U S A 113:E4857-66 (2016). PubMed: 27482109